
         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         

         
{"id":"gen-1758181696-sFFbY0o4AkSIdWpOOvw9","provider":"Meta","model":"meta-llama/llama-3.3-8b-instruct:free","object":"chat.completion","created":1758181700,"choices":[{"logprobs":null,"finish_reason":"stop","native_finish_reason":"stop","index":0,"message":{"role":"assistant","content":"Based on the provided text, here is the extracted information in JSON format:\n\n```\n{\n  \"filename\": \"apixaban-accord-epar-product-information_en.pdf\",\n  \"Document Type\": \"SMPC (Summary of Product Characteristics)\",\n  \"Product Name\": \"Apixaban Accord\",\n  \"Active Substance(s)\": \"Apixaban\",\n  \"Strength\": \"2.5 mg, 5 mg\",\n  \"Pharmaceutical Form\": \"Film-coated tablet\",\n  \"Route of Administration\": \"Oral\",\n  \"Indications\": \"Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism\",\n  \"Posology\": \"The recommended dose is 2.5 mg twice daily for patients with non-valvular atrial fibrillation, 5 mg twice daily for the first 7 days followed by 2.5 mg twice daily for treatment of deep vein thrombosis and pulmonary embolism, and 2.5 mg twice daily for prevention of recurrent deep vein thrombosis and pulmonary embolism\",\n  \"Contraindications\": \"Hypersensitivity to the active substance or to any of the excipients, active clinically significant bleeding, hepatic disease associated with coagulopathy and clinically relevant bleeding risk\",\n  \"Special Warnings and Precautions\": \"Haemorrhage risk, interaction with other medicinal products affecting haemostasis, use of thrombolytic agents for the treatment of acute ischemic stroke, patients with prosthetic heart valves, patients with antiphospholipid syndrome\",\n  \"Marketing Authorisation Holder\": \"Accord Healthcare S.L.U.\",\n  \"Marketing Authorisation Number\": \"EU/1/20/1458/001, EU/1/20/1458/003, EU/1/20/1458/004, EU/1/20/1458/006, EU/1/20/1458/008, EU/1/20/1458/010, EU/1/20/1458/012, EU/1/20/1458/014, EU/1/20/1458/041, EU/1/20/1458/043\",\n  \"Date of First Authorisation\": \"23 July 2020\",\n  \"Date of Latest Renewal\": \"Not found\",\n  \"Shelf Life\": \"3 years\",\n  \"Storage Conditions\": \"This medicinal product does not require any special storage condition\",\n  \"Package Description\": \"PVC/PVdC -Aluminium blisters, HDPE bottle with polypropylene child resistant/continues threaded closure\",\n  \"Legal Category\": \"Not found\",\n  \"ATC Code\": \"Not found\",\n  \"Manufacturers\": \"LABORATORI FUNDACIÃ“ DAU, Accord Healthcare Polska Sp. z.o.o., Pharmadox Healthcare Limited, Accord Healthcare single member S.A.\",\n  \"Excipients\": \"Lactose, cellulose microcrystalline, croscarmellose sodium, sodium laurilsulfate, magnesium stearate, lactose monohydrate, hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172), iron oxide red (E172)\"\n}\n```\n\nNote that some fields, such as \"Date of Latest Renewal\", \"Legal Category\", and \"ATC Code\", were not found in the provided text.","refusal":null,"reasoning":null}}],"usage":{"prompt_tokens":66231,"completion_tokens":745,"total_tokens":66976}}